在重症 COVID-19 患者中，加用洛匹那韦-利托那韦联合常规治疗未能改善 28 天死亡率。

In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.

机构信息

University of Alberta, Edmonton, Alberta, Canada (A.S.).

出版信息

Ann Intern Med. 2021 Jan;174(1):JC3. doi: 10.7326/ACPJ202101190-003. Epub 2021 Jan 5.

DOI:10.7326/ACPJ202101190-003

PMID:33395331

Abstract

RECOVERY Collaborative Group. Lancet. 2020;396:1345-52. 33031764.

摘要

RECOVERY 协作组。柳叶刀。2020；396：1345-52. 33031764.

相似文献

In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.在重症 COVID-19 患者中，加用洛匹那韦-利托那韦联合常规治疗未能改善 28 天死亡率。

Ann Intern Med. 2021 Jan;174(1):JC3. doi: 10.7326/ACPJ202101190-003. Epub 2021 Jan 5.

Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.COVID-19 门诊患者的早期抗病毒治疗（FLARE）：一项随机对照试验研究方案的结构化总结。

Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.

Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。

Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.

An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.高剂量干扰素β-1a与低剂量干扰素β-1a（基础治疗方案）相比对中度至重度COVID-19的有益效果研究：一项随机对照试验研究方案的结构化总结

Trials. 2020 Oct 26;21(1):880. doi: 10.1186/s13063-020-04812-2.

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.澳大利亚 COVID-19 试验（ASCOT）评估了洛匹那韦/利托那韦和/或羟氯喹治疗与标准治疗相比住院的 SARS-CoV-2 感染（COVID-19）患者的临床结局：一项随机对照试验研究方案的结构化总结。

Trials. 2020 Jul 14;21(1):646. doi: 10.1186/s13063-020-04576-9.

Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.早期 COVID-19 治疗试验：与住院时间、死亡率和相关费用的关系。

Swiss Med Wkly. 2020 Dec 31;150:w20446. doi: 10.4414/smw.2020.20446. eCollection 2020 Dec 14.

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.DisCoVeRy试验方案：住院成人COVID-19治疗安全性和有效性的多中心、适应性、随机试验

BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437.

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.洛匹那韦利托那韦在因 COVID-19 住院的患者中的应用（RECOVERY）：一项随机、对照、开放标签、平台试验。

Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4. Epub 2020 Oct 5.

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.评价法维拉韦和干扰素与洛匹那韦/利托那韦和干扰素在 COVID-19 中度患者中的疗效和安全性：一项随机对照试验研究方案的结构化总结。

Trials. 2020 Oct 27;21(1):886. doi: 10.1186/s13063-020-04747-8.

Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.干扰素 β1a 对比干扰素 β1b 和常规治疗方案治疗中重度 COVID-19 成人患者的效果：一项随机对照试验研究方案的结构化总结。

Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.

引用本文的文献

Codivir suppresses SARS-Cov-2 viral replication and stabilizes clinical outcome: In vitro and Phase I clinical trial results.可迪维抑制新型冠状病毒复制并稳定临床结果：体外及I期临床试验结果

Discoveries (Craiova). 2022 Dec 31;10(4):e158. doi: 10.15190/d.2022.17. eCollection 2022 Oct-Dec.

Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19).《新型冠状病毒肺炎重型、危重型病例诊断与治疗专家共识》

J Intensive Med. 2022 Aug 26;2(4):199-222. doi: 10.1016/j.jointm.2022.07.001. eCollection 2022 Oct.

Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.替诺福韦，另一种用于治疗新型冠状病毒肺炎的价格低廉、广为人知且易于获取的老药新用。

Pharmaceuticals (Basel). 2021 May 11;14(5):454. doi: 10.3390/ph14050454.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在重症 COVID-19 患者中，加用洛匹那韦-利托那韦联合常规治疗未能改善 28 天死亡率。

In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献